OneCell Diagnostics is now 1Cell.Ai
OneCell Diagnostics is now 1Cell.Ai
We understand that every stakeholder in cancer care—from clinicians to researchers to biopharma—faces unique challenges. Our AI-driven, single-cell multi-omics platform delivers customizable, real-time insights designed to meet the needs of each audience.
Empowering Real-Time, Personalized Cancer Care
We provide clinicians with non-invasive, advanced diagnostic tools to detect cancer earlier, guide treatment decisions, and monitor patient progress.
Key Benefits:
Accelerating Drug Development & Oncology Research
Our technology supports biopharma and research partners with deep molecular insights and scalable data solutions to advance clinical trials, biomarker discovery, and targeted therapies.
Key Benefits:
Empowering KOLs & Researchers with Real-Time Multi-Omics Intelligence
We equip oncology thought leaders and translational researchers with scalable tools to accelerate discovery, decode tumor biology, and validate biomarkers with precision and speed.
Key Benefits:
True single-cell and ctDNA platforms for high-resolution tumor profiling
AI-enabled biomarker discovery and multi-omics data integration
Customizable pipelines for exploratory, preclinical, or clinical research
Access to integrated consoles (iDiscover™) for data interrogation and insight generation
Personalized Insights for Better Outcomes
Our AI-powered, single cell diagnostics provide cancer patients with earlier detection, more precise treatment planning, and continuous monitoring—empowering clinicians to deliver care tailored to each patient’s unique cancer profile.
Key Benefits:
Empowering clinicians with real-time molecular data to guide diagnosis and treatment.
Providing researchers and labs with unprecedented resolution to study tumor biology and heterogeneity.
Accelerating biomarker identification and validation for biopharma and clinical trials.
Fostering a unified ecosystem where clinicians, researchers, and partners leverage shared insights to improve patient outcomes.
